MacroGenics | MGNX - Ativo Circulante





Ativo Circulante Alterar Data
AbbVie USD 33.53B 4.47B 2026-03
Amgen USD 31.48B 2.42B 2026-03
AstraZeneca USD 29.61B 890M 2026-03
Biogen USD 9.19B 216.3M 2026-03
Bristol-Myers Squibb USD 27.21B 2.18B 2026-03
Daiichi Sankyo JPY 2.1T 218.5B 2025-12
Eli Lilly USD 54.84B 794M 2026-03
Genmab DKK 2.88B 1.59B 2025-12
Geron USD 498.53M 21.74M 2026-03
Gilead Sciences USD 18.64B 1.25B 2026-03
J&J USD 59.17B 3.55B 2026-03
Karyopharm Therapeutics USD 103.15M 13.4M 2025-12
MacroGenics USD 182.52M 37.42M 2026-03
Merck USD 35.02B 8.5B 2026-03
Pfizer USD 42.82B 76M 2026-03
Puma Biotechnology USD 143.58M 7M 2025-09
Regeneron Pharmaceuticals USD 18.21B 187.3M 2026-03
Roche Holding CHF 38.73B 3.03B 2025-12
Xencor USD 482.85M 116.97M 2026-03